(Alliance News) - Oxford Nanopore Technologies PLC on Thursday touted the progress of a research group in Australia that has just received genomic funding for a project using Oxford Nanopore sequencing technology. Read More
(Alliance News) - Oxford Nanopore Technologies PLC shares surged after it received GBP70 million worth of backing from in vitro diagnostics partner bioMerieux SA. Read More
(Alliance News) - Oxford Nanopore Technologies PLC on Wednesday said revenue and profit fell in the first half as it came to the end of its Covid-19 testing contract. Read More
(Alliance News) - Oxford Nanopore Technologies PLC's decent first-half will soothe investor worries on life sciences market weakness and increased competition, analysts at Berenberg commented on Monday. Read More
(Alliance News) - Oxford Nanopore Technologies PLC on Monday said it expects to report half-year growth and the nanopore sequencing firm backed yearly guidance. Read More
(Alliance News) - Oxford Nanopore Technologies PLC said on Monday said it has reached an agreement with a national German science program to launch a study of the potential applications for nanopore-based sequencing to understand rare diseases. Read More
(Alliance News) - A recent revival of initial public offerings in London's equity markets is encouraging evidence that the city still holds appeal on the global stage, analysts contended. Read More
Oxford Nanopore Technologies PLC - Oxford, England-based company that develops and sells nanopore sequencing products - Signs a definitive deal with PathoQuest SAS to co-develop an 'integration site analysis' test. Says the test will provide a good manufacturing practice validated nanopore sequencing-based commercial testing service to the biopharma industry. Oxford Nanopore says the service is designed to address the needs of industrial developers and manufacturers of biological products. Read More
Oxford Nanopore Technologies PLC - Oxford, England-based company that develops and sells nanopore sequencing products - Enters a partnership with bioMerieux SA, a company in the field of in vitro diagnostics, to improve health outcomes. Says the partnership will explore opportunities to bring nanopore sequencing to the infectious disease diagnostics market. Read More
Oxford Nanopore Technologies PLC - Oxford, England-based company that develops and sells nanopore sequencing products - Chair Duncan Tatton-Brown buys 90,080 shares at GBP2.16 each in London on Thursday last week. In a separate transaction, Tatton-Brown buys 9,920 shares at GBP2.21 each on Tuesday this week. The shares are worth GBP216,251 in total. Read More
(Alliance News) - Oxford Nanopore Technologies PLC on Tuesday noted a National Institutes of Health Center for Alzheimer's & Related Dementias publication which showed a nanopore-based sequencing protocol delivered "scaled, accurate data". Read More
(Alliance News) - Oxford Nanopore Technologies PLC on Friday said it is participating in a cohort study led by the UK National Institute for Health and Care Research BioResource to explore human health and disease. Read More
